The FDA posted in its Adverse Event monitoring system that a 56-year-old male patient had hepatic failure following use of Eli Lilly’s (LLY) Foundayo. The case was reported to the FDA on April 30. Shares of Eli Lilly are down 3% to $936.03 in premarket trading.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly
- The Week That Was, The Week Ahead: Macro and Markets, May 3
- Eli Lilly & Co Soars on Obesity-Drug Power Play
- Eli Lilly price target raised to $1,344 from $1,327 at Morgan Stanley
- Eli Lilly price target raised to $1,230 from $1,205 at Cantor Fitzgerald